doiSerbia

Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C

Nešić Zorica I. (Institut za kliničku farmakologiju, farmakologiju i toksikologiju, Medicinski fakultet, Beograd)
Delić Dragan (Institut za infektivne i tropske bolesti, Klinički centar Srbije, Beograd)
Prostran Milica Š. (Institut za kliničku farmakologiju, farmakologiju i toksikologiju, Medicinski fakultet, Beograd)
Stojanović Radan M. (Institut za kliničku farmakologiju, farmakologiju i toksikologiju, Medicinski fakultet, Beograd)
Vučković Sonja M. (Institut za kliničku farmakologiju, farmakologiju i toksikologiju, Medicinski fakultet, Beograd)
Todorović Zoran M. (Institut za kliničku farmakologiju, farmakologiju i toksikologiju, Medicinski fakultet, Beograd)

Introduction Hepatitis C virus infection is a slowly progressive chronic disease and the most common cause of chronic liver disease. Presently, interferon alfa based therapies, with or without ribavirin, are standard treatment for chronic hepatitis C virus infection. The most troublesome psychiatric side effects of interferon therapy in our patients are: insomnia, irritability, anxiety, mood changes, short temper, emotional and affective lability, impaired cognitive function, apathy, loss of motivation and the most serious depression with or without suicidal ideas. Material and methods In our study we treated 82 patients chronically infected with HCV divided into 3 groups: the first group of 31 patients (20 male and 11 female) received IFN-alfa in standard doses of 3 MU three times a week (t.i.w) during 24 weeks; the second group of 36 patients (25 male and 11 female) received IFN-alfa, 3 MU t.i.w plus ribavirin 1000-1200 mg per day during 24 weeks; the third group of 15 patients (11 male and 4 female) received IFN-alfa, 3 MU t.i.w plus ribavirin 1000-1200 mg per day during 48 weeks. The follow-up period after therapy in all groups lasted 24 weeks. Results During treatment, we observed at least one psychiatric side effect in 21 (26%) patients: insomnia in 11 (13%), emotional and affective lability in 9 (11%), anxiety, irritability and short temper in 8 (10%), impaired cognitive function in 7 (8%) apathia and loss of motivation in 6 (7%) treated patients. Depression, the most serious side effect, was established in 8 (10%) patients. All of these side effects were observed during later stages of treatment (between 5th and 22nd weeks of treatment). The incidence of all psychiatric side effects was significantly higher in women than in men (p < 0,01). We observed higher prevalence of depression among patients with history of alcohol and drug abuse. Treatment was temporarily discontinued (from 2 to 4 weeks) in all patients with depression, but it was not permanently discontinuated in any patient due to psychiatric side effects. Conclusion Interferon causes psychiatric disorders that are usually mild and reversible. They disappear either spontaneously, while patients are still receiving therapy or after temporary cessation of interferon alfa therapy. .

Keywords: substance-related disorders, mental disorders, interferon Alfa, adverse effects, hepatitis c, chronic